After 18 years in charge, BioMarin Pharma’s chief executive and chairman, Jean-Jacques Bienaimé, has announced his retirement, with a high-powered replacement already lined up. Genentech CEO ...
BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...